Wellington Management Group LLP Tcr2 Therapeutics Inc. Transaction History

Wellington Management Group LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$2.4 - $4.71 $2 Million - $3.93 Million	-835,327 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$4.58 - $8.34 $8.75 Million - $15.9 Million	-1,909,849 Reduced 69.57%	835,327 $3.89 Million
Q3 2021 Nov 15, 2021	SELL	$8.44 - $18.35 $21.9 Million - $47.5 Million	-2,589,162 Reduced 48.54%	2,745,176 $23.4 Million
Q2 2021 Aug 16, 2021	BUY	$16.41 - $24.71 $6.54 Million - $9.84 Million	398,244 Added 8.07%	5,334,338 $87.5 Million
Q1 2021 May 17, 2021	BUY	$20.38 - $34.07 $24.1 Million - $40.3 Million	1,182,730 Added 31.51%	4,936,094 $109 Million
Q4 2020 Feb 12, 2021	BUY	$19.0 - $32.63 $33.5 Million - $57.5 Million	1,762,274 Added 88.51%	3,753,364 $116 Million
Q3 2020 Nov 16, 2020	BUY	$13.1 - $20.69 $26.1 Million - $41.2 Million	1,991,090 New	1,991,090 $40.5 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

Stay updated on Wellington Management Group LLP with notifications on news.